SCE Palliative Care: Mastering Terminal Symptom Management Guidelines

Why Terminal Symptoms Dominate the SCE

Palliative care is a high-yield topic across multiple Specialty Certificate Examinations — not only the Palliative Medicine SCE, but also Geriatric Medicine, Respiratory Medicine, and Medical Oncology SCEs. Terminal symptom management questions are virtually guaranteed, and they test more than just drug names. You need to know mechanisms, routes, dose adjustments for organ impairment, opioid conversions, and syringe driver compatibilities. This guide consolidates the essential guidelines from NICE (NG31), the European Association for Palliative Care (EAPC), and the Palliative Care Formulary (PCF) into one revision-ready resource.

1. Terminal Pain Management

The WHO Analgesic Ladder — Updated Approach

The classic three-step ladder remains the conceptual framework, but the 2022 EAPC update emphasises a critical change that SCE questions are increasingly testing:

• Step 1: Non-opioids (paracetamol, NSAIDs) ± adjuvants

• Step 2: Weak opioids (codeine, tramadol) ± non-opioids ± adjuvants

• Step 3: Strong opioids (morphine, oxycodone, fentanyl) ± non-opioids ± adjuvants

High-yield SCE point: Current EAPC guidance recommends moving directly from Step 1 to Step 3 for moderate-to-severe pain, bypassing weak opioids. The evidence shows weak opioids offer minimal additional benefit over optimised non-opioid regimens while adding side-effect burden.

Starting Morphine for Opioid-Naïve Patients

After 24 hours, calculate the total morphine consumed and convert two-thirds to a modified-release preparation given every 12 hours. The remaining one-third becomes the breakthrough dose.

Breakthrough dose formula: 1/6th to 1/10th of the total 24-hour regular dose.

Opioid Conversion — The Most Tested Calculation

Memorise these equianalgesic ratios:

Critical SCE scenarios:

• Renal impairment (eGFR < 30): Morphine and diamorphine are contraindicated — active metabolites accumulate. Switch to fentanyl or alfentanil (both safe in renal failure as they have no active metabolites)

• Hepatic impairment: Start at 50% of the standard dose and titrate cautiously. Fentanyl and alfentanil are preferred as they are less affected by hepatic metabolism at terminal doses

• Opioid rotation: If switching due to intolerable side effects (not inadequate analgesia), reduce the equianalgesic dose by 25–50% for incomplete cross-tolerance

Adjuvant Analgesics — Matching Drug to Pain Type

2. Terminal Breathlessness (Dyspnoea)

Stepwise Approach

Non-pharmacological (always start here):

• Upright, forward-leaning positioning

• Cool air / fan directed at the face (activates trigeminal nerve receptors)

• Breathing control techniques

• Anxiety management and reassurance

Pharmacological — First-line: Opioids

Key SCE point: Systemic opioids, when titrated appropriately, do not cause clinically significant respiratory depression in terminal dyspnoea. This misconception is frequently tested, and the correct answer is that opioids reduce the perception of breathlessness via central mechanisms without compromising respiratory drive at appropriate doses.

Pharmacological — Second-line: Benzodiazepines (for associated anxiety)

• Lorazepam 0.5–1 mg sublingual PRN

• Midazolam 2.5–5 mg SC every 1–4 hours PRN, or 10–20 mg/24h via CSCI

Key SCE point: Benzodiazepines should only be added when opioids alone are insufficient and anxiety is a significant component. They are not first-line for terminal dyspnoea.

Oxygen therapy — NICE NG31 guidance:

• Only beneficial if the patient is hypoxaemic (SpO₂ < 90% on air)

• In non-hypoxic patients, opioids are superior to oxygen

• A trial of oxygen vs air is reasonable, but do not assume oxygen helps everyone

3. Nausea and Vomiting — Matching Antiemetic to Cause

This is one of the highest-yield palliative care topics in SCE. The key principle is mechanism-based prescribing:

Critical SCE Compatibility Points

1. Metoclopramide + cyclizine = CONTRAINDICATED: Metoclopramide is a prokinetic (enhances gastric emptying), while cyclizine has antimuscarinic effects that reduce gut motility. Combining them cancels each other out.

2. Complete bowel obstruction: Avoid prokinetics entirely. Use cyclizine (reduces vomiting centrally) and consider octreotide (reduces gut secretions via somatostatin receptor agonism). Ranitidine or PPI may reduce gastric secretions.

3. Levomepromazine 6.25 mg SC OD is the broad-spectrum agent for resistant nausea/vomiting. It blocks D₂, 5-HT₂, 5-HT₃, H₁, and M₁ receptors. Maximum useful dose is around 25–50 mg/24h.

4. Ondansetron should be used cautiously in palliative care — it can cause constipation, which may worsen nausea. Reserve for specific 5-HT₃-mediated causes (e.g., chemotherapy, post-operative).

4. Terminal Agitation and Restlessness

First: Identify and Treat Reversible Causes

Pharmacological Management — Stepwise

Step 1: Midazolam (first-line)

• PRN: 2.5–5 mg SC every 1–2 hours

• If ≥3 PRN doses in 24h: start CSCI at 10–20 mg/24h

• Titrate by 25–50% every 24h (maximum commonly 60 mg/24h)

Step 2: Add haloperidol (if delirium component)

• 2.5–5 mg SC PRN, or 5–15 mg/24h CSCI

Step 3: Switch to levomepromazine (if midazolam insufficient)

• PRN: 12.5–25 mg SC

• CSCI: 25–100 mg/24h

Key SCE point: Do NOT use lorazepam or diazepam for terminal agitation. They have slow onset (15–30 minutes) and long half-lives, making titration difficult. Midazolam is preferred for its rapid onset (2–3 minutes SC) and short duration, allowing dose titration.

5. Respiratory Secretions ("Death Rattle")

Management Principles

1. Explain to family: The patient is usually not distressed by the secretions — the noisy breathing is more distressing to observers. This is a critical communication point.

2. Reposition: Lateral position with head slightly down if safe

3. Review fluids: Reduce or stop unnecessary IV fluids

4. Pharmacological: Antimuscarinics — but treat early; they are far less effective once secretions have accumulated

Antimuscarinic Selection — Know the Difference

Critical SCE distinction: Hyoscine butylbromide (Buscopan) does NOT cross the blood-brain barrier because it is a quaternary ammonium compound. Hyoscine hydrobromide (Kwells/scopolamine) DOES cross the BBB and may worsen delirium. This is one of the most frequently tested distinctions in SCE.

6. Terminal Delirium

Delirium affects up to 80% of patients in the last days of life. SCE questions typically differentiate between:

• Hyperactive delirium: agitation, restlessness, hallucinations — easy to spot

• Hypoactive delirium: lethargy, reduced responsiveness — frequently missed

• Mixed delirium: fluctuating features

Management Algorithm

Non-pharmacological (always first):

• Familiar environment, family presence

• Reassurance and reorientation

• Address sensory impairment (glasses, hearing aids)

Pharmacological (only if distressing to patient):

Key SCE point: NICE NG31 does not recommend benzodiazepines for delirium unless there is severe agitation unresponsive to antipsychotics, or the patient is in the terminal phase requiring sedation (where midazolam is appropriate).

7. Syringe Driver Drug Compatibility — A Guaranteed SCE Topic

The continuous subcutaneous infusion (CSCI) via syringe driver is the mainstay of terminal care when the oral route is lost. SCE questions test drug compatibility extensively.

Common Compatible Combinations

Key Compatibility Rules

1. Diluent: Water for injection is the default. Not normal saline — many drugs precipitate in saline, especially cyclizine and diamorphine combinations.

2. Maximum volume: Typically 20 mL over 24 hours in a standard syringe driver (some use 10 mL).

3. When in doubt, check the PCF: Always consult the Palliative Care Formulary for compatibility data.

4. Cyclizine: Can precipitate with diamorphine at higher concentrations. Keep total volume ≥ 10 mL and use water for injection.

5. Avoid mixing more than 3 drugs in a single syringe without checking compatibility.

8. Key Guidelines to Know for SCE

NICE NG31: The Five Priorities for Care

These frequently appear in SCE questions:

1. Recognise: The possibility that a person may die within the coming days/hours

2. Communicate: sensitively and honestly, involving patient and family

3. Involve: patients and those important to them in decisions

4. Plan: personalised care with individualised symptom management

5. Support: those important to the patient, including after death

9. Palliative Care Emergencies — Must-Know for SCE

While these are covered in depth in other guides, here's a quick checklist:

1. Malignant spinal cord compression (MSCC): Dexamethasone 16 mg immediately + urgent MRI (within 24h) + radiotherapy. Time to treatment = neurological outcome.

2. Hypercalcaemia of malignancy: Treat if symptomatic and corrected calcium > 2.6 mmol/L. IV bisphosphonate (zoledronic acid 4mg IV or pamidronate 60–90mg IV). Stop only if calcium is rising or symptoms persist. Denosumab if bisphosphonate-resistant or renal failure.

3. Superior vena cava obstruction: Dexamethasone 4–8 mg OD ± stent ± radiotherapy. Anticoagulation if thrombus-related.

4. Neutropenic sepsis: Immediate broad-spectrum antibiotics within 1 hour (per NICE CG151). Do not wait for cultures.

5. Massive haemorrhage: Dark towels (practical), midazolam 10 mg SC (sedation), apply pressure if accessible. Non-absorbable dressings.

10. High-Yield Revision Checklist

Use this as your final pass before the exam:

✅ Opioid conversion calculations (oral to SC, morphine to oxycodone, transdermal equivalents)
✅ Drug selection for renal impairment (fentanyl/alfentanil — NOT morphine)
✅ Matching antiemetic to nausea/vomiting cause (mechanism-based approach)
✅ Metoclopramide + cyclizine = contraindicated (opposing effects)
✅ Hyoscine butylbromide vs hydrobromide (BBB penetration difference)
✅ Syringe driver compatibility — water for injection, not saline
✅ Terminal dyspnoea: opioids first-line, oxygen only if hypoxic
✅ Terminal agitation: midazolam first-line (not lorazepam/diazepam)
✅ Delirium: haloperidol first-line (not benzodiazepines)
✅ Levomepromazine as broad-spectrum antiemetic (6.25 mg starting dose)
✅ Death rattle: treat early, explain to family
✅ NICE NG31 five priorities for care
✅ Bowel obstruction: no prokinetics, use cyclizine ± octreotide
✅ Advance decisions and Mental Capacity Act provisions
✅ MSCC, hypercalcaemia, SVCO management protocols

Common SCE Pitfalls — What Catches Candidates Out

1. Choosing morphine for a patient with eGFR 25: Wrong. Morphine metabolites (M6G and M3G) accumulate in renal failure, causing toxicity. The correct answer is fentanyl or alfentanil.

2. Prescribing metoclopramide with cyclizine: This is a classic error. The prokinetic effect of metoclopramide is antagonised by the antimuscarinic effect of cyclizine. Choose one or the other based on the likely cause.

3. Using hyoscine hydrobromide for death rattle in a patient with delirium: The hydrobromide crosses the BBB and may worsen delirium. Use butylbromide or glycopyrronium instead.

4. Starting oxygen for breathlessness in a non-hypoxic patient: NICE NG31 is clear — oxygen should only be used if there is hypoxaemia. In non-hypoxic dyspnoea, opioids are superior.

5. Forgetting to reduce the dose when rotating opioids: Always reduce by 25–50% for incomplete cross-tolerance when switching between opioids.

6. Using saline as the diluent in a syringe driver with cyclizine: This will cause precipitation. Water for injection is the standard diluent.

7. Missing reversible causes of terminal agitation: Always check for urinary retention (bladder scan), constipation (PR examination), and drug toxicity before reaching for sedatives.

How to Practise These Topics for SCE

1. Weekly opioid calculation drills: Set yourself 5 conversion questions per week. These are guaranteed marks in the exam.

2. Create a one-page summary table for nausea/vomiting — cause, receptors, drug, dose. Pin it above your desk.

3. Practise syringe driver scenarios: Take a clinical vignette and prescribe the full CSCI regimen. Check your answer against the PCF.

4. Review NICE NG31 at least once before the exam. Know the five priorities cold.

5. Use question banks with palliative care modules. Focus on application-style questions, not just recall.

6. Study with a palliative care formulary open: The PCF is your best friend for compatibility, dosing, and route information.

Conclusion

Terminal symptom management is one of the most rewarding areas to revise for SCE. The questions are predictable in structure, the guidelines are clear, and with systematic preparation, these become reliable marks rather than a source of anxiety.

The exam rewards candidates who can apply guidelines to clinical scenarios — not just recite drug names. So when you see a palliative care question, take a breath, identify the mechanism, match the drug to the cause, and select the answer that reflects guideline-based, patient-centred care. That's what the SCE is really testing: not whether you can memorise doses, but whether you can practise safe, evidence-based palliative medicine.